Update on Medical Therapies of Nasopharyngeal Carcinoma by Soumaya Labidi et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
10 
Update on Medical Therapies of  
Nasopharyngeal Carcinoma  
Soumaya Labidi, Selma Aissi, Samia Zarraa,  
Said Gritli, Majed Ben Mrad,  
Farouk Benna and Hamouda Boussen 
Faculty of Medicine of Tunis,  
University of Tunis 
Tunisia 
1. Introduction 
Nasopharyngeal carcinoma (NPC) is a common head and neck cancer in most of the 
countries of the Mediterranean Area (MA) and North Africa (NA). Its incidence is variable 
from <1 in sporadic areas to 2-7/100000 in NA and MA to 20-30/100000 in Southern China 
and Southeast Asia (Boussen et al,2010; Lee et al, 1992). It’s different from other head and 
neck cancers due to its particular epidemiology, natural history and therapeutic 
considerations (Boussen et al, 2010; Lee et al, 1992). 
It’s highly radiosensitive and chemosensitive. Loco-regional radiotherapy (RT) remains the 
primary treatment for early stage disease (T1-T2, N0, N1), while combined chemotherapy-
radiotherapy became the gold therapeutic standard in locally advanced disease i.e T3-T4, 
N2-N3 (Boussen et al, 2010; Lee et al, 1992; Baujat et al, 2006). Combined treatment leads to a 
significant improvement on overall and disease-free survivals, but NPC remains at a high 
metastatic risk, requiring the search for new salvage therapeutic protocols (Boussen et al, 
2010; Lee et al, 1992: Xu et al, 2010). This paper will focus on recent data on epidemiology 
and progresses on medical therapies in NPC. 
2. Transitional epidemiology of NPC  
NPC represents 2 to 5% of all cancers in males, it is second to laryngeal cancer in most of the 
Mediterranean countries ant its incidence varying from 1 in Lebanon, Egypt, Greece, Turkey 
to 2-5/100000 in North Africa (NA), where it’s characterized by a bimodal age repartition 
with a first peak at adolescence (Boussen et al, 2010; Ben Abdallah M, 2010). This high 
frequency of children and adolescents affected by NPC in Tunisia open the discussion to 
reach the maximum cure rate with minimal late aftereffects (Boussen et al, 2010). Endemic 
NPC is highly frequent in south-east Asia with an incidence > 20/100000 compared to NA 
(Tse et al, 2006). During the last 10 years, authors from Singapore reported a decrease of 
NPC incidence especially for UCNT type. This epidemiologic transition could be attributed 
to a socio-economic level increase as well as diet modification, such as salted fish (rich in 
nitrosamines) consumption decrease (Tse et al, 2006). The same trend have been observed 
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(Sun et al,2005) from 1992 to 2002 for the incidence Rates of NPC among Chinese Americans 
Living in Los Angeles County and the San Francisco Metropolitan Area with a decrease of 
37% for men by 37% and only 1% in women(7).   Conversely, male and female NPC world 
age-standardized incidence reported to be 27.5/105 and 11.3/105 respectively, seems to be 
stable from 1970-2007 in the Chinese endemic area of Zhongshan (Wei et al, 2010). In Tunisia 
(Ben Abdallah M,2010), we are observing, like in Singapore, a decreasing incidence of NPC 
and a projection from the North Tunisia cancer registry for 2024 suggests a significant drop 
of NPC incidence, while breast and colon cancer will clearly increase.  
3. Staging and classification 
During the last 20 years, NPC natural history became more known in term of loco-regional 
extension as well as metastatic disease with technical improvements of flexible 
nasofibroscopes and modern imagery, such as magnetic resonance imagery and Pet-
scan(Chan et al,2011). This better definition of loco-regional disease extension leads to 
successive actualizations (1997, 2002 then 2009), of the more used TNM UICC anatomo-
clinical classification, more adapted to discriminate between the different T and N 
prognostic stages and eventually to adjust therapeutic protocols according to risk group 
(Union for International Cancer Control,2009).  
T1 Nasopharynx, oropharynx or nasal cavity (was T2a*) without parapharyngeal extension 
T2 Parapharyngeal extension (was T2b*)  
T2a Tumour extends to oropharynx and/or nasal cavity without parapharyngeal extension 
T2b Tumour with parapharyngeal extension 
T3 Bony structures of skull base and/or paranasal sinuses 
T4 Intracranial, cranial nerves, hypopharynx, orbit, infratemporal fossa/masticator space 
N1 Unilateral cervical, unilateral or bilateral retropharyngeal lymph nodes, above 
supraclavicular fossa; < 6 cm  
N2 Bilateral cervical above supraclavicular fossa; < 6 cm  
N3 Metastasis in lymph node(s), >6 cm in dimension (N3a) or in the supraclavicular fossa 
(N3b)>6 cm 
7th TNM classification of UICC (International Union against Cancer, 2009)-AJCC, American 
Joint Committee on Cancer. *Recent modification 
4. Chemotherapy 
Systemic chemotherapy (CT) in NPC is indicated because disease is confined to 
nasopharynx in < 10% of cases (Lee et al; 1992), while parapharyngeal extension, skull base 
and intracranial involvement are reported in 80% and 25 to 35% and pathologic cervical 
nodes are present in 75 to 90% of patients, increasing the risk of initial metastases in 
advanced stages (Lee et al;1992; Sham et al,1991; Teo et al,1992). CT have been used since the 
eighties in palliative intent with few devoted phase II trials and the most active agents are 
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cisplatin, 5-fluorouracil (5-FU), doxorubicin, epirubicin, bleomycin, mitoxantrone, 
methotrexate and vinca alkaloids or more recently ifosfamide or gemcitabine(Bensouda et 
al,2011;Boussen et al,2010;You et al,2011). CT have been used from the nineties  as adjuvant 
then  primary CT(PCT) in NPC(Bachouchi et al,1990) confirming the chemosensitivity of 
NPC with a high rate of radiologic/endoscopic objective responses to PCT (Bachouchi et 
al,1990; Ekenel et al,2011).  
5. Radiotherapy 
RT remains is the mainstay of of NPC treatment due to its radiosensibility (Boussen et al, 
2010; Chan et al, 2010; Lee et al, 1992). Loco-regional RT targets primary tumor, its 
regional extension and both neck sides (levels Ib–V, and retropharyngeal nodes). 
Consensual dose is around 70 Gy with dose-fractions of 1.8 to 2Gy, indicated for 
sterilization of bulky tumor volume and 50–60 Gy or 46–60 Gy for areas at high risk (Lee 
et al, 1992; Chan et al, 2010).  
6. Concomitant CT-RT 
The results of concurrent chemoradiotherapy (CCRT) Intergroup study 0099, made 
gradually this combined approach as a standard in the treatment of patients with stage III 
and IV NPC (Al Sarraf et al, 1998; Chan et al, 2010). Within the randomized other studies, 
several meta-analysis and a pooled data analysis reported a significant improvement of 
survival in NPC patients treated by CTRT versus RT alone (Baujat et al, 2006). The NPC 
meta-analysis had shown the superiority of concomitant scheme vs neoadjuvant 
chemotherapy. It concerned 1753 patients with N1> 2cm, N2> 3cm, N3, T4, PS 0- 1, WHO 2-
3 and a mean age of 46 years. The follow-up was < 5 years for 2 trials (299 pts), 5-9 years for 
6 (1454 pts) and a median follow-up of 6 years for the whole population. Delivered 
radiotherapy were for tumor: 65-74 Gy, for N0 : 50-66 Gy and for N+ 60-76 Gy, by using a 
“classical” technique and a boost for residual N associated to concomitant cisplatin-based 
CT in all trials. Authors reported a benefit of concomitant scheme by increasing 5-year OS 
from 56% to 62% and EFS from 42% to 52% significantly better than neoadjuvant 
chemotherapy. Recently a meta-analysis focused on South East Asian phase III trials of CT-
RT from the NPC endemic area. 1608 patients were collected from seven trials (Zhang L et 
al, 2010) and they reported Risk ratios (RRs) of 0.63 (95% CI, 0.50 to 0.80), 0.76 (95% CI, 0.61 
to 0.93) and 0.74 (95% CI, 0.62 to 0.89) for 2, 3 and 5 years OS respectively in favor of the 
CCRT group. Concerning the 3-years absolute number of locoregional recurrence rate 
(LRR), a significant overall benefit in favor of the addition of chemotherapy was found with 
RR of 0.67 (95% CI, 0.49 to 0.91). A significant decrease of metastatic risk was also observed 
in term of 3-years absolute number of distant metastasis rate (DMR) with a RR of 0.71. The 
RRs were larger than that detected in the previously reported meta-analysis (including both 
endemic and non-endemic), and authors concluded that “the relative benefit of CCRT in 
endemic population might be less than that from previous meta-analyses”. 
6.1 CT Protocols of concomitant CT-RT 
The schemes used for CTRT are mainly based on “Al Sarraf” schedule with Cisplatin 
100mg/m2, every 3 weeks on D1,22,43 or weekly Cisplatin at 40mg/m2(Chan Scheme), 
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who’s the most frequently used in MA and NA, while radiotherapy doses is usually ≥66Gy 
(1.8-2Gy/Fx/d, 5Fx/wk) for primary nasopharyngeal tumor and its extensions + additional 
boosts to the parapharyngeal space, the primary or nodal sites not exceeding 20Gy. Since 10 
years, CCRT is now recognized and applied as the better therapeutic approach for locally 
advanced NPC (Al Sarraf,1998 ; Chan et al,2010 ). 
6.2 Acute and late toxicities of CT-RT 
CT-RT compared to PCT, however increased significantly acute grade 3-4 toxicity at the 
end of combined treatment i.e mucositis, radiodermitis, dysphagia and consequently 
severe weight loss (WL) in most of the open or randomized studies (Table 1). This acute 
toxicity reduced considerably the compliance of weekly concomitant cisplatin, that was 
administered during the 6 weeks of CT-Rt in 94%,88%,74%,35%,7% and 3% for weeks  
1 to 6 in Hui study (Hui et al,2009). The frequency of severe WL > 5-10% is probably 
underestimated by many authors and requires sometimes nasal tube feeding or parenteral 
nutrition as well as delay in the planned protocol. In a Chinese study (Qiu et al, 2011), of 
patients treated by CT-RT for NPC, 56% had at baseline, a mean 5% WL evaluated at  
6.9 Kg after CT-RT (range 2.1-12.6 kg). Xerostomia is one of the most frequent sequelae 
after salivary gland irradiation and Intensity-Modulated RT permits to reach a high  
tumor control rate, but also to reduce severity and frequency of xerostomia (Lee et al, 
2009). 
 
 Author/year Hui/2010       Lee/2010         Zheng/2010 
 After PCT        An ---  --  1.7% 
   Neutr 97%  --  6.8% 
   Thr --  --  --  
   N/V 8.8%  --  5.1%  
 After CT-RT 
   An 8.8 19.2 19     1  39% 
   Neutr 26.4 15.3 32%  1%  35.6% 
   Thr   2%    0% 
   Mucos 23.5 7.7 61%  48% --- 
   N/V 8.8 7.7 18%   1% 47.1% 
   WL   27%  27% 
   Rad   20%   16%   
 Late toxicities 
   Dys ---   3.8%   1%  0%  3.4%  
   Xer 32.4 30.8% ---    ---  91.5% 
   Skin 11.8 19.2%            4%   5%  
   Subc 20.6 11.5% 
   HL 8.8  11.5%              6%  ---  3.4% 
   Otit    21  15%  3.5% 
   Hypoth   8%   6%  6.8% 
   SC          5.9  3.8% 
 
Table 1. Acute and late toxicities after CT-RT. 
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Despite many technical advances in RT, late toxicities i.e mainly xerostomia, cervical 
subcutaneous fibrosis, trismus, hearing loss of less frequently second cancers are observed 
decreasing the Quality of Life of long-term survivors from NPC, specially those treated in 
childhood or adolescence (Boussen et al,2010; Xiao et al,2011). 
6.3 What next after concomitant CT-RT? 
After the era of exclusive CT-RT, appeard the next generation protocols associating PCT 
followed by CT-RT (Fountzilas et al, 2011, Hui et al, 2009). PCT protocols included 
“classical” 5FU-cisplatin, anthracyclin-cisplatin or more recently taxanes-cisplatin 
associations (Table 2). Hui and al, reported their results on 65 patients treated cisplatin-
docetaxel (DC) protocol followed by CCRT vs CCRT alone. They observed a significant 
survival benefit at 2 years for the DC arm (93% vs 76%, p = .013). Others studies including 
also taxanes, showed a benefit for overall and disease-free survival of patients treated for 
NPC in MA are currently varying from 66 to 94% and 63 to 88.2% (table 3). Many of these 
studies have a short Follw-up, but OS and DFS rates seems to be promising probably better 
than those reported in exclusive CT-RT. In Tunisia, a prospective GORTEC French trial is 
ongoing, comparing 2 cycles of primary TPF followed by chemoradiotherapy vs CCRT with 
weekly cisplatin (40mg/m2) in advanced(N2-3, T3-4). 
 
Author/year Nb CT  RT  ORPCT  ORCT-RT OS/DFS 
Zheng/2010 60 Ned/FU IMRT        -----    95.3%            3 yr 85.5/75%  
   Ned Conc 70/55-60 
Fountzilas 72 CPE-CRT       66-70/50-66    70%    83%           3 yr 66.6/64.5  
2011  69 CRT              --------         -----           85%           3 yr 71.8/63.5 
Hui  34 DC-CRT          70/50-60   76,5%     97.1%          3 yr 94.1/88.2% 
2009  31 CRT                70/50-60          ----   100%              3 yr 69.2/63% 
CPE :Cisplatin-Paclitaxel-Epirubicin, DC : Docetaxel-cisplatin, CRT : Concomitant chemo-radiotherapy, 
Ned : Nedaplatin. 
Table 2. Therapeutics results of open or randomized studies of PCT followed by CT-RT. 
7. Tumor volume in NPC: A new prognostic factor? 
Instead of the classical T,N,Age,Sex and histologic type, prognostic value of Primary Tumor 
Volume(PTV), measured by CT-scan have been explored for NPC in 112 patients with Stage 
I-IVB NPC treated by IMRT (Chen et al, 2011). The mean PTV was 33.9 ± 28.7 ml and 
classified from V1 to V4 (from 15.65 to 50,5ml). It impacted on 5-year overall survival who 
varies from 88.5, 83.3, 82.4 to 54.5% for V1 to V4 from, showing that V1-V4 are clearly 
separated from V4 (p = 0.014). Cox proportional hazards regression model analysis showed 
that a PTV >50 ml was an independent risk factor for radiotherapy (risk ratio = 3.485, P = 
0.025). In 56 Turkish patients with locally advanced NPC, PTV have been calculated by 
measuring tumor diameters by CT and MR film hardcopies computed as an ellipsoid 
(V=4/3·π·d1·d2·d3) to obtain the diameter-based volume(Sarisahin et al, 2011). They 
reported in the monovariate analysis, that primary tumor volume have a significant 
predictive value on DFS and DMFS, if tumor volume < 20ml, DFS was 60% vs 0% if > 
60ml(p=0.007). The residual tumor volume (RTV) at first control after treatment was also 
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found to be a significant prognostic factor on LRRFS (p=0.03). However Nasopharyngeal 
PTV alone is missing the volume of satellite cervical  nodes that have probably an important 
prognostic value. 
8. Recurrent/metastatic disease 
NPC failures are mainly metastatic, to bones, lungs and liver and loco-regional relapses 
became more rare due to the high loco-regional control rate obtained by loco-regional RT 
(Leung et al,2005; Cvitkovic et al,1993). In metastatic situations, NPC remains 
chemosensitive to cisplatin, adriamycin, 5Fluorouracil or more recently taxanes, gemcitabine 
or oral capecitabine(Boussen et al,1991,2010;You et al,2011;Bensouda et al,2011). Prolonged 
survival after palliative CT and/or RT could be observed in patients with bone metastases 
in case of bone MTS only and less than 4 sites involved (Fandi et al,2000;Cao et al,2011). In 
isolated bone metastases, prolonged responses under biphosphonates plus CT have been 
also reported, with a significant reduction of skeletal events and better (11.5 vs 5.5 months, 
P < 0.001) progression-free survival and overall survival (23.5 vs. 17.5 months, P < 0.001) of 
combined vs chemotherapy alone group. (Jin et al,2011). Even in case of lung MTS disease, 
different prognostic groups could be identified according to size and numbers of metastatic 
nodules (Cao X et al, 2011).  
9. Effective screening for NPC? 
Some efforts have been done oriented for early detection in relatives of patients considered 
at high risk for NPC, according to their viral DNA and anti-EBV profile (Baizig et al,2011;Liu 
et al,2011). Sophisticated endoscopic technique have been also tested to detect easily early 
stages of NPC (Lin et al,2011, Lin et al,2011).  
10. Conclusion 
NPC is a very interesting within the other head and neck cancers, occurring in young 
patients non-smokers/non drinkers and significant improvement of therapeutic results have 
been reached during the last 30 years, 5 years-OS increasing from 20-30% to more than 75% 
with the recent protocols of CT-RT or PCT followed by CT-RT that included taxanes 
(Boussen et al, 2010, Chan et al,2010). Overexpression of EGRF, present in more than 70% of 
NPC leads to the use of Cetuximab as adjuvant concomitant or maintenance therapy (Yang 
Y  et al, 2011). Anti-angiogenesis therapies like Pazopanib have been also tested without 
proven efficacy(Lim et al,2011). The significant survival improvement made NPC a more 
curable disease and efforts were made to reduce late sequelae specially in children and 
adolescents and to affect minimally quality of life after combined chemo-radiotherapy (Fang 
et al,2011;Marucci et al,2011;Shueng et al,2011). 
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